Connecting global priorities: biodiversity and human health: a state of knowledge review
Abstract: Chagas disease is caused by infection with the protozoan Trypanosoma cruzi, and although over 100 years have passed since the discovery of Chagas disease, it still presents an increasing problem for global public health. A plethora of information concerning the chronic phase of human Chaga...s disease, particularly the severe cardiac form, is available in the literature. However, information concerning events during the acute phase of the disease is scarce. In this review, we will discuss the current status of acute Chagas disease cases globally, the immunological findings related to the acute phase and their possible influence in disease outcome, and reactivation of Chagas disease in immunocompromised individuals, a key point for transplantation and HIV invection management.
more
Review
Triccas and Counoupas Pneumonia (2016) 8:18; DOI 10.1186/s41479-016-0020-z
PLoS ONE 13(8): e0202499. https://doi.org/10.1371/journal.pone.0202499
This was a school-based cross-sectional study conducted in 2015 among 305 school children aged 7–16 years from two primary schools located in Ilemela and Magu Districts, north-western Tanzania. Single stool and urine samples w...ere collected from each participant and examined for the presence of Schistosoma mansoni eggs, parasite antigen, and parasite DNA using KK thick smears, POC-CCA tests, and real-time PCR, respectively.
more
La evidencia disponible a nivel internacional sobre el uso de un segundo refuerzo muestra una mayor duración de la respuesta inmune y una disminución de la internación y la mortalidad por COVID 19 en la población de adultos mayores y huéspedes inmunocomprometidos. Por otra parte, el personal de... salud se beneficiaría considerando el mayor riesgo de exposición y la caída de la respuesta inmune con el tiempo. En base a lo señalado previamente se recomienda incorporar y
priorizar un segundo refuerzo al esquema de vacunación contra la COVID-19 del:
- Personal de salud independientemente de la edad
- Personas de 50 años o mayores
- Personas de 12 años o más con inmunocompromiso
A la vez, se progresará de manera escalonada y simultánea con la vacunación de segundo refuerzo del:
- Personal estratégico
- Personas de 18 a 49 años con factores de riesgo
Continuando en la estrategia de segundo refuerzo todas las personas a partir de los 18 años. Las personas gestantes con indicación de segundo refuerzo, se recomienda vacunas de plataforma de ARNm (Pfizer-BioNTech o Moderna)
more
New England Journal of Medicine
April 9, 2021
DOI: 10.1056/NEJMoa2104840
A fact sheet from the National Academies and the U.S. Department of Homeland Security on human pathogens, biotoxins and agricultural threats
Campaña Nacional de Vacunación contra la COVID-19
The purpose of this pocketbook is to provide clear guidance on current best management practices for VHF across health-care facilities
This learning report attempts to understand the drivers for, and barriers to, effective implementation as well as review the experiences of Start Fund members in responding to these outbreaks to support evidence-based decision-making within the Start Network at project, crisis, and system level. Spe...cifically, it analyses the effectiveness, efficiency, and relevance of Start Fund disease outbreak responses by reviewing and analysing funding, decision-making and response activities before ultimately exploring implications and recommendations.
more
The proposed roadmap includes components and recommended actions to eliminate these neglected infectious diseases from the Americas.
Phytochem Rev (2023) 22:1691–1806
Plants have a lot of potential and will continue to contribute feasible, effective medicines and/or pesticides; more research is warranted to fully explore their future applications
EBioMedicine. 2016 Jun 16. pii: S2352-3964(16)30276-6. doi: 10.1016/j.ebiom.2016.06.020. Open Access